AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

11 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology

23 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

05 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

01 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Healthcare Conference

31 May 2023 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

16 May 2023 18:53:36 By Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

29 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

17 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

10 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

21 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH

08 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

10 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022

07 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

11 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

19 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

14 Sep 2022 20:07:00 By Nasdaq GlobeNewswire